Myasthenia gravis is a rare and debilitating condition that affects the neuromuscular junction, causing muscle weakness and fatigue. Traditional treatment options for this disease have often involved invasive procedures or systemic immunosuppressive therapies. However, UCB's Rystiggo revolutionizes the management of myasthenia gravis with its subcutaneous administration, providing a more convenient and patient-friendly alternative. By targeting the disease-specific molecule FcRn, Rystiggo aims to reduce the production of the autoantibodies responsible for muscle weakness, thereby alleviating the symptoms and improving patients' quality of life.

With the approval of Rystiggo, UCB has once again demonstrated its commitment to pioneering innovative therapies that address unmet medical needs. This significant achievement not only underscores UCB's expertise in neurology but also highlights its dedication to improving the lives of patients worldwide. As the pharmaceutical industry continues to advance, UCB's Rystiggo sets a new standard in myasthenia gravis treatment, offering renewed hope to those affected by this challenging condition.